{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:12:57Z","timestamp":1790435577021,"version":"4.1.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.jaad.2007.08.030","type":"journal-article","created":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T17:17:07Z","timestamp":1196788627000},"page":"94-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis"],"prefix":"10.1016","volume":"58","author":[{"given":"Mark","family":"Lebwohl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Kalb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa Boer","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warwick L.","family":"Morison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Van Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald D.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melodie","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2007.08.030_bib1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/09546630600954594","article-title":"Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis","volume":"17","author":"Bhosle","year":"2006","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2007.08.030_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.clindermatol.2005.01.009","article-title":"Psoriasis: a fresh look","volume":"23","author":"Galadari","year":"2005","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib3","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1002\/art.11277","article-title":"Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events","volume":"48","author":"Yazici","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2007.08.030_bib4","unstructured":"Halverstam CP, Lebwohl M. Practical management and monitoring of psoriasis in patients on biologic therapy. Psoriasis Forum. In press."},{"key":"10.1016\/j.jaad.2007.08.030_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMp068282","article-title":"Guidance for guidelines","volume":"356","author":"Steinbrook","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2007.08.030_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaad.2005.05.039","article-title":"Etanercept and demyelinating disease in a patient with psoriasis","volume":"54","author":"Sukal","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib7","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2007.08.030_bib8","first-page":"239","article-title":"Adalimumab-associated multiple sclerosis","volume":"34","author":"Bensouda-Grimaldi","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study","volume":"53","author":"The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2007.08.030_bib10","first-page":"1202","article-title":"Etanercept induced multiple sclerosis and transverse myelitis","volume":"33","author":"Al Saieg","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib11","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1345\/aph.1G279","article-title":"Optic neuritis with concurrent etanercept and isoniazid therapy","volume":"39","author":"Noguera-Pons","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2007.08.030_bib12","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1212\/WNL.57.10.1885","article-title":"Onset of multiple sclerosis associated with anti-TNF therapy","volume":"57","author":"Sicotte","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2007.08.030_bib13","first-page":"1457","article-title":"Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab","volume":"33","author":"Ruiz-Jimeno","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib14","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1212\/01.WNL.0000158681.29117.8B","article-title":"Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers","volume":"64","author":"Richez","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2007.08.030_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.mcg.0000155126.82171.32","article-title":"Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis","volume":"39","author":"Enayati","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jaad.2007.08.030_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00054725-200401000-00004","article-title":"Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease","volume":"10","author":"Thomas","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2007.08.030_bib18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist [review] [summary for patients in Ann Intern Med 2003;138:I48]","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2007.08.030_bib19","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2007.08.030_bib20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1388-9842(02)00121-6","article-title":"Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH","volume":"4","author":"Coletta","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaad.2007.08.030_bib21","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2007.08.030_bib22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib23","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2007.08.030_bib24","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.healun.2004.06.021","article-title":"Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling","volume":"23","author":"Berry","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jaad.2007.08.030_bib25","doi-asserted-by":"crossref","first-page":"H1813","DOI":"10.1152\/ajpheart.00036.2004","article-title":"In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure","volume":"287","author":"Moe","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jaad.2007.08.030_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00296-006-0215-3","article-title":"The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists","volume":"27","author":"Cole","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaad.2007.08.030_bib27","series-title":"Alefacept (Amevive) [package insert]","year":"2006"},{"key":"10.1016\/j.jaad.2007.08.030_bib28","series-title":"Efalizumab (Raptiva) [package insert]","year":"2006"},{"key":"10.1016\/j.jaad.2007.08.030_bib29","series-title":"Etanercept (Enbrel) [package insert]","year":"2007"},{"key":"10.1016\/j.jaad.2007.08.030_bib30","series-title":"Infliximab (Remicade) [package insert]","year":"2006"},{"key":"10.1016\/j.jaad.2007.08.030_bib31","series-title":"Adalimumab (Humira) [package insert]","year":"2007"},{"key":"10.1016\/j.jaad.2007.08.030_bib32","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumor necrosis factor blockers do not increase overall tumor risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib33","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2007.08.030_bib34","first-page":"691","article-title":"Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization","volume":"91","author":"Quartuccio","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.jaad.2007.08.030_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease","volume":"44","author":"Mackey","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaad.2007.08.030_bib36","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/ard.2004.026252","article-title":"Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment","volume":"64","author":"Thonhofer","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib37","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/rheumatology\/41.10.1194","article-title":"Non-Hodgkin's lymphoma in a\u00a0patient with refractory dermatomyositis which had been treated with infliximab","volume":"41","author":"Roddy","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2007.08.030_bib38","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Hematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib39","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2007.08.030_bib40","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/gut.2005.075937","article-title":"Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicenter matched pair study","volume":"55","author":"Biancone","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2007.08.030_bib41","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jaad.2004.07.031","article-title":"Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy","volume":"51","author":"Fryrear","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib42","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1067\/mjd.2001.117725","article-title":"Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy","volume":"45","author":"Smith","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2007.08.030_bib43","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.jaad.2003.11.044","article-title":"Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab","volume":"50","author":"Esser","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib44","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archderm.141.7.861","article-title":"No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years","volume":"141","author":"Lebwohl","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib45","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1034\/j.1600-0609.2003.00115.x","article-title":"Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor [erratum in Eur J Haematol 2004;72:306]","volume":"71","author":"Kuruvilla","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaad.2007.08.030_bib46","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2006.07437.x","article-title":"Efalizumab-induced autoimmune pancytopenia","volume":"155","author":"Tom","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib47","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-143-10-200511150-00028","article-title":"Immune thrombocytopenia associated with efalizumab therapy for psoriasis","volume":"143","author":"Warkentin","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2007.08.030_bib48","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gut.2007.123547","article-title":"Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease","volume":"56","author":"Salar","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2007.08.030_bib49","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/kel204","article-title":"TNFalpha blocker-induced thrombocytopenia","volume":"45","author":"Pathare","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2007.08.030_bib50","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s10067-006-0229-y","article-title":"A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap\/rheumatoid arthritis","volume":"26","author":"Hamaguchi","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib51","doi-asserted-by":"crossref","first-page":"W","DOI":"10.7326\/0003-4819-139-3-200308050-00021-w4","article-title":"Severe neutropenia and thrombocytopenia associated with infliximab","volume":"139","author":"Vidal","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2007.08.030_bib52","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s10067-006-0415-y","article-title":"Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges","volume":"26","author":"Montane","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib53","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2230.2006.02086.x","article-title":"Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis","volume":"31","author":"Wahie","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib54","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/00044011-200626110-00008","article-title":"Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis","volume":"26","author":"Ierardi","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jaad.2007.08.030_bib55","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/ard.2004.031187","article-title":"Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy","volume":"64","author":"Wendling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib56","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2007.08.030_bib57","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib58","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ibd.20035","article-title":"Occult hepatitis B and infliximab-induced HBV reactivation","volume":"13","author":"Madonia","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib59","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease","volume":"30","author":"Michel","year":"2003","journal-title":"Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","article-title":"Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha","volume":"64","author":"Eriksson","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib61","first-page":"2557","article-title":"Induction of autoantibodies during prolonged treatment with infliximab","volume":"30","author":"Louis","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib62","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/art.10876","article-title":"Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy","volume":"48","author":"De Rycke","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2007.08.030_bib63","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2133.2006.07639.x","article-title":"A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity","volume":"156","author":"Poulalhon","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib64","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00296-006-0271-8","article-title":"Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results","volume":"27","author":"Caramaschi","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaad.2007.08.030_bib65","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/01.MIB.0000186408.07769.78","article-title":"Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease","volume":"11","author":"Nancey","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib66","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/08916930400021378","article-title":"Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab","volume":"38","author":"Elkayam","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaad.2007.08.030_bib67","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/art.21190","article-title":"Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis","volume":"52","author":"De Rycke","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2007.08.030_bib68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jbspin.2004.03.003","article-title":"Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate","volume":"72","author":"Sellam","year":"2005","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaad.2007.08.030_bib69","first-page":"756","article-title":"Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab","volume":"22","author":"Allanore","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib70","doi-asserted-by":"crossref","first-page":"R535","DOI":"10.1186\/ar1440","article-title":"Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study","volume":"6","author":"Ferraro-Peyret","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2007.08.030_bib71","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","article-title":"Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha","volume":"64","author":"Eriksson","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00296-007-0379-5","article-title":"Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis","volume":"28","author":"Fusconi","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaad.2007.08.030_bib73","first-page":"24","article-title":"Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy","volume":"33","author":"Comby","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib74","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/rheumatology\/kei227","article-title":"Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis","volume":"45","author":"Pallotta","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2007.08.030_bib75","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2007.08.030_bib76","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1016\/S0190-9622(03)00869-7","article-title":"Cutaneous lupus erythematosus induced by infliximab","volume":"52","author":"High","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib77","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","article-title":"Anti-TNF-alpha-induced systemic lupus syndrome","volume":"22","author":"Debandt","year":"2003","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib78","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3346\/jkms.2006.21.5.946","article-title":"Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis","volume":"21","author":"Kang","year":"2006","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jaad.2007.08.030_bib79","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/kel227","article-title":"Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level","volume":"45","author":"van Rijthoven","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2007.08.030_bib80","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.rhu.0000152148.55133.ba","article-title":"Drug-induced lupus after treatment with infliximab in rheumatoid arthritis","volume":"11","author":"Benucci","year":"2005","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib81","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/rheumatology\/kei220","article-title":"Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab","volume":"45","author":"Perez-Garcia","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2007.08.030_bib82","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaad.2007.08.030_bib83","first-page":"268","article-title":"Infliximab-induced lupus or rheumatoid arthritis (RA) overlapping with systemic lupus erythematosus (SLE) unmasked by infliximab","volume":"22","author":"Novak","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib84","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2230.2004.01471.x","article-title":"Discoid lupus erythematosus-like eruption induced by infliximab","volume":"29","author":"Stratigos","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib85","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1590-8658(03)00448-1","article-title":"Infliximab-induced lupus in Crohn's disease: a case report","volume":"35","author":"Sarzi-Puttini","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib86","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2230.2003.01411.x","article-title":"Etanercept-induced systemic lupus erythematosus","volume":"28","author":"Swale","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib87","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00054725-200305000-00005","article-title":"A lupus-like syndrome associated with infliximab therapy","volume":"9","author":"Klapman","year":"2003","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib88","first-page":"276","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis","volume":"21","author":"Lepore","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib89","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.11033","article-title":"Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis","volume":"48","author":"Carlson","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2007.08.030_bib90","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1191\/0961203302lu236cr","article-title":"Drug-induced lupus following treatment with infliximab in rheumatoid arthritis","volume":"11","author":"Favalli","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2007.08.030_bib91","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/ard.61.11.1031","article-title":"New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis","volume":"61","author":"Cairns","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib92","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2007.08.030_bib93","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3109\/s10165-006-0561-8","article-title":"Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus","volume":"17","author":"Hayat","year":"2007","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib94","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1177\/0961203306070970","article-title":"Efficacy and safety of etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy","volume":"15","author":"Micheloud","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2007.08.030_bib95","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2007.08.030_bib96","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1081\/IPH-120037721","article-title":"Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report","volume":"26","author":"Principi","year":"2004","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.jaad.2007.08.030_bib97","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.immunol.19.1.93","article-title":"Immunology of tuberculosis","volume":"19","author":"Flynn","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaad.2007.08.030_bib98","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/rheumatology\/kel447","article-title":"Development of active tuberculosis following initiation of infliximab despite appropriate prophylaxis","volume":"46","author":"Raychaudhuri","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2007.08.030_bib99","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib100","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib101","first-page":"217","article-title":"Miliary tuberculosis following infliximab therapy for Crohn's disease: a case report and review of the literature","volume":"69","author":"Stas","year":"2006","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.jaad.2007.08.030_bib102","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.2214\/AJR.05.0412","article-title":"On the AJR viewbox: pseudotumoral colonic tuberculosis complicating rheumatoid arthritis treated with a tumor necrosis factor antagonist","volume":"186","author":"Lesnik","year":"2006","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jaad.2007.08.030_bib103","first-page":"1657","article-title":"Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid","volume":"30","author":"Parra Ruiz","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib104","first-page":"112","article-title":"Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFalpha (adalimumab) treatment","volume":"63","author":"Efde","year":"2005","journal-title":"Neth J Med"},{"key":"10.1016\/j.jaad.2007.08.030_bib105","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2230.2004.01716.x","article-title":"Successful treatment of recalcitrant pyoderma gangrenosum with infliximab complicated by tuberculosis despite negative screening tests","volume":"30","author":"Uthman","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib106","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1742-1241.2004.00061.x","article-title":"Disseminated tuberculosis complicating anti-TNF-alpha treatment","volume":"58","author":"Dimakou","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jaad.2007.08.030_bib107","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/rheumatology\/keh074","article-title":"Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis","volume":"43","author":"Armbrust","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2007.08.030_bib108","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2007.08.030_bib109","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00134-003-1867-z","article-title":"Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate","volume":"29","author":"van der Klooster","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jaad.2007.08.030_bib110","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2007.08.030_bib111","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/030097402317255372","article-title":"Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment","volume":"31","author":"Mayordomo","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib112","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00417-007-0549-x","article-title":"Tuberculous uveitis after treatment with etanercept","volume":"245","author":"Fonollosa","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jaad.2007.08.030_bib113","first-page":"526","article-title":"Mycobacteria tuberculosis peritonitis associated with etanercept therapy","volume":"21","author":"Manadan","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib114","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor","volume":"39","author":"Mohan","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib115","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s10067-005-0164-3","article-title":"Tuberculosis peritonitis in a patient with rheumatoid arthritis treated with adalimumab","volume":"26","author":"Gutierrez-Macias","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib116","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2007.08.030_bib117","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2013California, 2002-2003","volume":"53","author":"Centers for Disease Control and Prevention","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2007.08.030_bib118","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1164\/rccm.200402-232OC","article-title":"Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts","volume":"170","author":"Brock","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2007.08.030_bib119","first-page":"15","article-title":"Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection","volume":"52","author":"Mazurek","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2007.08.030_bib120","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1164\/rccm.200502-196OC","article-title":"Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection","volume":"172","author":"Ferrara","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2007.08.030_bib121","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jaad.2003.07.023","article-title":"Methotrexate and reactivation tuberculosis","volume":"51","author":"Lamb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib122","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/rheumatology\/40.3.341","article-title":"Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis","volume":"40","author":"Binymin","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2007.08.030_bib123","doi-asserted-by":"crossref","unstructured":"Vachharajani TJ, Oza UG, Phadke AG, Kirpalani AL. Tuberculosis in renal transplant recipients: rifampicin sparing treatment protocol. Int Urol Nephrol 2002-2003;34:551-3.","DOI":"10.1023\/A:1025693521582"},{"key":"10.1016\/j.jaad.2007.08.030_bib124","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0190-9622(03)01836-X","article-title":"CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study","volume":"49","author":"Gottlieb","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib125","first-page":"1356","article-title":"Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept","volume":"31","author":"Mease","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib126","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2007.08.030_bib127","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/j.semarthrit.2003.10.003","article-title":"The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Elkayam","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2007.08.030_bib128","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/rheumatology\/kel366","article-title":"Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients","volume":"46","author":"Kapetanovic","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2007.08.030_bib129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2005.036434","article-title":"Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers","volume":"65","author":"Fomin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2007.08.030_bib130","first-page":"272","article-title":"Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab","volume":"34","author":"Kaine","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib131","first-page":"3096","article-title":"Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone","volume":"56","author":"Visvanathan","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2007.08.030_bib132","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/CMR.16.3.357-364.2003","article-title":"Vaccinations for\u00a0adult solid-organ transplant recipients: current recommendations and protocols","volume":"16","author":"Duchini","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2007.08.030_bib133","unstructured":"Centers for Disease Control and Prevention. Adult immunization schedule. Available at: www.cdc.gov\/nip\/recs\/adult-schedule.htm#print. Accessed October 1, 2006."},{"key":"10.1016\/j.jaad.2007.08.030_bib134","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3949\/ccjm.68.4.337","article-title":"Immunizations in adult immunocompromised patients: which to use and which to avoid","volume":"68","author":"Avery","year":"2001","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jaad.2007.08.030_bib135","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0889-857X(05)70087-9","article-title":"Vaccination of the immunosuppressed adult patient with rheumatologic disease","volume":"25","author":"Avery","year":"1999","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2007.08.030_bib136","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/247553030612a00105","article-title":"Initiating and monitoring patients on biologic therapy for psoriasis, beyond the FDA: our more cautious approach","volume":"12","author":"Routhouska","year":"2006","journal-title":"Psoriasis Forum"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962207013151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962207013151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:09:04Z","timestamp":1759270144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962207013151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0190962207013151"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2007.08.030","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2007.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}